maganin ciwon daji na renal cell

Maganin ciwon daji na renal cell (RCC) ya ƙunshi hanyoyi daban-daban, ciki har da tiyata, maganin da aka yi niyya, immunotherapy, da maganin radiation. Zabin magani ya dogara da dalilai kamar matakin ciwon daji, lafiyar majiyyaci gabaɗaya, da abubuwan da ake so. Ganowa da wuri da sa baki akan lokaci suna da mahimmanci don inganta sakamako.Fahimtar Ciwon ƙwayar ƙwayar ƙwayar cutaCiwon daji na renal (RCC) shine mafi yawan nau'in ciwon daji na koda a cikin manya. Ya samo asali ne a cikin rufin tubule na kusa, sashin koda wanda ke tace jini kuma yana cire kayan datti. Duk da yake ainihin dalilin RCC ba koyaushe yake bayyana ba, wasu abubuwan haɗari suna da alaƙa da ƙara yuwuwar haɓaka cutar. Wadannan abubuwan haɗari sun haɗa da shan taba, kiba, hawan jini, da yanayin kwayoyin halitta kamar cutar von Hippel-Lindau (VHL). A Shandong Baofa Cibiyar Nazarin Ciwon daji, mun himmatu wajen samar da cikakkun bayanai da ci gaba magani options for RCC patients.Types of Renal Cell CarcinomaThere are several subtypes of RCC, each with distinct characteristics and potentially different responses to magani. Mafi yawan nau'ikan subtypes sun haɗa da: Share RCC cell: Wannan shine nau'in mafi yaduwa, yana lissafin kusan 70-80% na lokuta. Papillary RCC: Nau'i na biyu mafi na kowa, yana wakiltar kusan 10-15% na lokuta. Chromophobe RCC: Nau'in da ba shi da yawa, wanda ya kai kusan kashi 5% na lokuta. Tattara tashar RCC: Wani nau'i na RCC da ba kasafai ba magani tsarin kula da RCC ya dogara da abubuwa da yawa, gami da matakin ciwon daji, lafiyar mai haƙuri gabaɗaya, da takamaiman nau'in RCC. Na kowa magani Hanyoyin da suka haɗa da tiyata, maganin da aka yi niyya, immunotherapy, da kuma maganin radiation. maganin ciwon daji na renal cell, musamman lokacin da ciwon daji ya kasance a cikin koda. Zaɓuɓɓukan tiyata sun haɗa da: Radical nephrectomy: Wannan ya haɗa da cire gaba ɗaya daga cikin koda da abin ya shafa, tare da nama da ke kewaye da su kamar glandar adrenal da ƙwayoyin lymph. Partanal nephrectomy: Wannan ya haɗa da cire ƙari kawai da ɗan ƙaramin gefe na nama mai lafiya, adana yawancin koda gwargwadon yiwuwa. An fi son wannan tsarin don ƙananan ciwace-ciwacen ƙwayoyi ko lokacin da majiyyaci yana da koda guda ɗaya kawai. Maganin da aka yi niyya da aka yi niyya magunguna ne waɗanda ke keɓance ƙwayoyin ƙwayoyin cuta da ke da hannu wajen haɓakar ƙwayar cutar kansa da rayuwa. Waɗannan hanyoyin kwantar da hankali na iya yin tasiri musamman a cikin ci gaba na RCC. Magungunan da aka yi niyya gama gari sun haɗa da: Masu hana VEGF: Wadannan kwayoyi suna toshe hanyar haɓakar haɓakar jijiyoyi (VEGF), wanda ke da mahimmanci don ƙirƙirar sabbin hanyoyin jini waɗanda ke ba da ciwace-ciwace. Misalai sun haɗa da sunitinib (Sutent), sorafenib (Nexavar), pazopanib (Votrient), axitinib (Inlyta), da cabozantinib (Cabometyx). masu hana mTOR: Wadannan kwayoyi suna toshe manufar rapamycin (mTOR) hanyar dabbobi masu shayarwa, wanda ke daidaita ci gaban sel da metabolism. Misalai sun haɗa da temsirolimus (Torisel) da Everolimus (Afinitor) .ImmunotherapyImmunotherapy yana amfani da ƙarfin tsarin garkuwar jiki don yaƙar kansa. Magungunan rigakafi na RCC sun haɗa da: Masu hana rigakafin rigakafi: Wadannan kwayoyi suna toshe sunadaran da ke hana tsarin garkuwar jiki hari daga kwayoyin cutar kansa. Misalai sun haɗa da nivolumab (Opdivo), pembrolizumab (Keytruda), ipilimumab (Yervoy), da atezolizumab (Tecentriq). Nivolumab sau da yawa ana haɗuwa tare da ipilimumab don cututtuka masu tasowa. Cytokines: Interleukin-2 mai girma (IL-2) da interferon-alpha (IFN-α) sune cytokines waɗanda zasu iya ƙarfafa tsarin rigakafi. Duk da haka, waɗannan magungunan na iya samun tasiri mai mahimmanci kuma ba a saba amfani da su ba a yanzu saboda samun sababbin maganin rigakafi.Radiation TherapyRadiation far yana amfani da haskoki mai ƙarfi don kashe kwayoyin cutar kansa. Ba yawanci na farko ba ne maganin ciwon daji na renal cell, amma ana iya amfani da shi don sarrafa ciwo ko wasu alamun da ke haifar da ci gaban ciwon daji wanda ya yadu zuwa wasu sassan jiki. Wani lokaci ana amfani da shi bayan tiyata idan akwai haɗarin ciwon daji zai dawo ko kuma idan an kasa cire wasu daga cikin ƙari. Stereotactic body radiation therapy (SBRT) yana ba da allurai masu yawa na radiation zuwa wurin da aka yi niyya daidai kuma a wasu lokuta ana amfani da su don ciwace-ciwacen koda.Mataki na Renal Cell Carcinoma da JiyyaMataki na RCC shine maɓalli mai mahimmanci don ƙayyade daidaitattun da ya dace. magani kusanci. Matakin yana dogara ne akan girman da wurin da ƙari yake, ko ya yadu zuwa nodes na lymph na kusa, da kuma ko ya daidaita zuwa gabobin da ke da nisa.Stage I Renal Cell Carcinoma Ciwon daji yana iyakance ga koda kuma yana da 7 cm ko ƙasa da diamita. Magani yawanci ya haɗa da cire ƙwayar ƙwayar cuta ta tiyata, ko dai ta hanyar ɓarna ko radical nephrectomy.Stage II Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ya fi 7 cm girma amma har yanzu yana tsare a cikin koda. Magani Yawanci yakan ƙunshi nephrectomy mai tsattsauran ra'ayi.Stage III Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon daji ya yadu zuwa nodes na Lymph nodes ko kuma ya girma zuwa manyan jijiya ko nama kewaye. Magani na iya haɗawa da nephrectomy mai raɗaɗi, rarraba kumburin lymph, da yuwuwar maganin adjuvant (misali, maganin da aka yi niyya ko immunotherapy).Stage IV Carcinoma Renal Cell CarcinomaCan daji ya daidaita ga gabobin nesa, kamar huhu, ƙasusuwa, ko kwakwalwa. Magani Zaɓuɓɓukan na iya haɗawa da tiyata don cire ƙwayar farko (cytoreductive nephrectomy), maganin da aka yi niyya, immunotherapy, radiation far, ko haɗin waɗannan hanyoyin. Gwajin asibiti kuma na iya zama zaɓi.Rayuwa tare da Ciwon Kankara na Renal Cell Rayuwa tare da RCC na iya gabatar da ƙalubale iri-iri, na jiki da na zuciya. Yana da mahimmanci a sami tsarin tallafi mai ƙarfi da samun damar samun cikakkiyar kulawar likita. Marasa lafiya na iya fuskantar illa daga magani, irin su gajiya, tashin zuciya, gudawa, da rashn fata. Sarrafa waɗannan illolin wani muhimmin sashi ne na kula da ciwon daji. Bugu da ƙari, kiyaye salon rayuwa mai kyau, gami da daidaitaccen abinci da motsa jiki na yau da kullun, na iya taimakawa wajen haɓaka jin daɗin rayuwa gaba ɗaya. A Cibiyar Nazarin Ciwon daji ta Shandong Baofa, ƙungiyarmu ta sadaukar da kai tana ba da kulawa ta tausayi da keɓantacce magani yana shirin taimaka wa marasa lafiya sarrafa RCC da inganta ingancin rayuwarsu. Muna cikin yankin Innovation na Jinan, kuma manufarmu ta yi daidai da dabarun 'Made in China 2025'. Ci gaba na Kwanan nan a Maganin Ciwon Ciwon Ƙwayoyin Ƙwayoyin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙwara magani yana ci gaba da haɓakawa, tare da haɓaka sabbin hanyoyin kwantar da hankali da hanyoyin. Ci gaban kwanan nan sun haɗa da: Haɗin Immunotherapy: Haɗa magungunan rigakafi daban-daban, irin su nivolumab da ipilimumab, sun nuna ingantaccen sakamako a wasu marasa lafiya tare da RCC ci gaba. Ingantattun hanyoyin kwantar da hankali: Ana haɓaka sabbin ƙarni na hanyoyin kwantar da hankali tare da ingantacciyar inganci da ƙarancin illa. Maganin Keɓaɓɓen: Masu bincike suna aiki don gano masu amfani da kwayoyin halitta wanda zai iya taimakawa wajen hango ko wanene marasa lafiya zasu iya amsawa ga takamaiman maganis.Prognosis for Renal Cell CarcinomaTsarin RCC ya bambanta dangane da matakin ciwon daji, lafiyar majiyyaci gabaɗaya, da martani ga magani. Ganowa da wuri da sa baki akan lokaci suna da mahimmanci don inganta sakamako. Marasa lafiya tare da RCC na gida waɗanda aka yi wa tiyata suna da babban damar warkewa. Duk da haka, tsinkayar ba ta da kyau ga marasa lafiya tare da RCC mai ci gaba. Bincike mai gudana yana mai da hankali kan haɓaka sabbin kuma mafi inganci maganis don inganta tsinkaya ga duk marasa lafiya tare da RCC.Clinical Gwajin gwaji na asibiti binciken bincike ne wanda ke kimanta sababbi. maganis ko hanyoyin don RCC. Shiga cikin gwaji na asibiti na iya ba da damar yin amfani da hanyoyin kwantar da hankali waɗanda har yanzu ba su da yawa. Marasa lafiya masu sha'awar ƙarin koyo game da gwaje-gwajen asibiti yakamata suyi magana da likitan su.Misali Bayanan: Adadin Rayuwa ta Mataki na 5-Shekaru 5 Matsayin Tsira Mataki na 81-93% Mataki na II 74-91% Mataki na III 53-83% Mataki na IV 8-20% Source: American Cancer Society (www.cancer.org)